drugset

drugset / Trial / NCT01027013

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

NCT01027013 ↗

Phase 2 Completed 220 enrolled Kubota Vision Inc. Otsuka Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.

Timeline

Start: 2009-12
Primary completion: 2010-10
Completion: 2010-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rebamipide	Small molecule	2 %	Other

Indications